Bridgene Biosciences Inc. has signed a strategic collaboration and licensing agreement with Takeda Pharmaceutical Co. Ltd. to discover small-molecule drug candidates against targets in immunology and neurology.

Researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Miramoon Pharma SL and affiliated organizations published the preclinical characterization of FKBP12 ligand MP-010 and evaluated its efficacy in models of amyotrophic lateral sclerosis.

Epstein-Barr virus (EBV) infection is a recognized risk factor that is now regarded as a prerequisite for the development of multiple sclerosis (MS). Recently, significant advances have been made in clarifying the precise mechanism by which EBV leads to the pathogenic features of MS. Now, a new study may have tied up more loose ends. Researchers from the University of Helsinki have mapped the immune landscape of deep cervical lymph nodes (dCLN) in patients recently diagnosed with MS.

Researchers from New York University and affiliated organizations have detailed data for C-2230, a Cav2.2 channel blocker being developed for the treatment of pain.